



Preimplantation Genetic Testing for Couples with Balanced Chromosomal Rearrangements

Sachin Shetty¹, Jiny Nair¹, Jnapti Johnson¹, Navya Shetty¹, Ajay Kumar J¹, Nirmala Thondehalmath², Deepanjali Ganesh², Vidyalakshmi R Bhat², Sajana M², Anjana R², Rajsekhar Nayak^{1,2}, Devika Gunasheela^{1,2}, Jayarama S Kadandale^{1,3}, Swathi Shetty^{1,3*}

1- Tattvagene Pvt. Ltd., Bangalore, India

2- Gunasheela Surgical and Maternity Hospital, Bangalore, India

3- Centre for Human Genetics Biotech Park, Bengaluru, India

Abstract

Background: Chromosomal rearrangements play an important role in infertility. Carriers of chromosomal rearrangements have a lower chance of producing normal or balanced gametes due to abnormal segregation of chromosomes at meiosis, which leads to recurrent spontaneous abortions and infertility. Preimplantation genetic testing for structural chromosome rearrangements (PGT-SR) is offered to couples who have balanced chromosomal rearrangements in order to select embryos with a balanced karyotype prior to implantation, thereby increasing the chances of pregnancy. The purpose of the current study was to assess the outcomes of PGT-SR in patients carrying various balanced chromosomal rearrangements and to assess their clinical pregnancy outcome after in vitro fertilization (IVF).

Methods: In this study, infertile couples with balanced chromosomal abnormalities undergoing PGT-SR were retrospectively analyzed at a single fertility center from January 2016 to December 2019.

Results: PGT-SR was performed on 87 embryos from 22 couples in whom one partner carried a balanced translocation or an inversion. Fifty-seven (65.5%) of these embryos had unbalanced or sporadic aneuploidies, 30 (34.5%) embryos were normal or chromosomally balanced, which were then transferred in 18 couples. A higher rate of unbalanced translocations in comparison to sporadic aneuploidies was observed in couples with reciprocal translocation. The live birth rate per embryo transfer was found to be 66.6% (12/18).

Conclusion: PGT-SR is a useful tool in selecting normal or balanced embryos for transfer in IVF, which could lead to a pregnancy by reducing the chance of miscarriages due to chromosome aneuploidy in couples with balanced chromosomal rearrangements.

Keywords: Aneuploidy, Balanced chromosomal rearrangements, In vitro fertilization, Inversion, Preimplantation genetic testing, Reciprocal translocation, Recurrent miscarriages, Robertsonian translocation.

To cite this article: Shetty S, Nair J, Johnson J, Shetty N, Kumar A, Thondehalmath N, et al. Preimplantation Genetic Testing for Couples with Balanced Chromosomal Rearrangements. *J Reprod Infertil.* 2022;23(3):213-223. <https://doi.org/10.18502/jri.v23i3.10013>.

* Corresponding Author:
Swathi Shetty, Centre for
Human Genetics Biotech
Park, Bengaluru, India
E-mail:
swathi@chg.res.in

Received: Aug. 8, 2021

Accepted: Oct. 8, 2021

Introduction

Reproductive genetic risk and infertility have become a global problem that affects both men and women with almost equal frequen-

cy. In fact, nearly 50% of infertility cases are due to genetic defects (1). The genetic causes of infertility are various, ranging from severe chromoso-

mal abnormalities to single-gene disorders. The results of cytogenetic studies have shown that 2-4% of infertile patients carry chromosomal abnormalities (2-4). Balanced chromosomal abnormalities are one of the causes of infertility and although carriers are phenotypically normal, they have a 50% risk of spontaneous abortions and a 20% risk of having offspring with abnormal karyotypes (5). Most IVF centers now routinely perform karyotyping of couples with infertility issues before beginning the IVF cycles. Guidelines have also been drawn up to help standardize protocols internationally (6). Therefore, karyotyping has become an obligatory biological examination in the management of all patients with infertility. Apart from reduced reproductive potential, carriers of chromosomal abnormalities increase the risk of pregnancy with a chromosomally unbalanced foetus leading to a miscarriage or the live birth of a child with congenital anomalies (7, 8).

PGT-SR is a technique applied in couples with balanced chromosomal rearrangements for the selection and transfer of chromosomally balanced or euploid embryos in an IVF cycle to improve the pregnancy outcome. There has been rapid improvement in the methodology used for PGT-SR, from traditional FISH to microarray (9) and most recently, next-generation sequencing (NGS), which has improved accuracy and reliability of methodologies; it has been proved to be the method of choice for performing chromosome screening of embryos (10, 11). The purpose of the current study was assessing the aneuploidy rate in a cohort of patients who were carriers of balanced chromosomal rearrangements. The current article details the karyotype abnormalities that were observed in couples undergoing IVF, outcomes of the chromosomal screening of embryos, and the result of performed embryo transfers.

Methods

Study subjects: This retrospective analysis included 22 patients in whom chromosomal abnormality was apparent in either of the couple and they had opted for PGT-SR from January 2016 to December 2019 in Gunasheela Surgical and Maternity Hospital, Bangalore, India. All couples were evaluated and counselled by infertility specialists and medical geneticists. The procedure and limitations of PGT-SR were explained to the couples. The study was approved by the institutional ethics committee and informed consent was obtained from all the participants.

Cytogenetic analysis: Karyotyping was carried out using cultured peripheral lymphocytes by the GTG-banding technique (12). For each case, ten high level-G banded metaphases (resolution ranging from 400-550) were analyzed following the International System for Human Cytogenetic Nomenclature (ISCN, 2013) (13). In cases of suspected mosaicism, ≥ 50 metaphases were examined. The chromosome polymorphism such as pericentric inversion of chromosome 9 was considered a normal variant (14).

Ovarian stimulation, oocyte retrieval, embryo culture, and embryo biopsy: All the participants underwent controlled ovarian stimulation, using either the long agonist, antagonist or flare protocol depending on the clinical scenario of the patient (15). The follicular response was monitored at regular intervals by transvaginal ultrasound scan and ovulation was induced with IU hCG 250 mcg when at least two follicles had reached a diameter of 17 mm. Ultrasound-guided oocyte retrieval was performed 34-36 hr after hCG injection. The aspirated follicular fluid was screened under the microscope to identify and assess the cumulus oocyte complex (COC). The COC was mechanically denuded using 150 μ l flexipet (Stripper tips, CooperSurgical, USA). Simultaneously, the semen sample obtained from the husband was processed using density gradient centrifugation or wash method in combination with the swim-up technique depending on the semen parameters. The intracytoplasmic sperm injection (ICSI), involving the injection of the matured oocyte with a single sperm was carried out using the standard protocol. The embryos were incubated in a Tri-gas incubator and cultured until day 5 in One-Step media (Vitromed, USA). In the PGT-SR group, the trophectoderm biopsy was performed using laser assisted hatching. Five to seven trophectoderm cells were dissected from each blastocyst and transferred into thin walled 0.2 ml PCR tubes containing 2 μ l 1X phosphate buffer solution and sent to our in-house genetics laboratory.

PGT-SR using NGS: NGS methodology was used to test for structural rearrangements in biopsied embryo samples on the Ion PGM system (Thermo Fisher Scientific, USA). Once the samples were received in the genetics laboratory, whole genome amplification (WGA) was carried out using the Ion Reproseq™ PGS kit. The barcodes were assigned as per the Ion Reproseq™ PGS kit protocol (Thermo Fisher Scientific, USA). Libraries were

pooled, purified using Agencourt Ampure XP beads, quantified, and templates were prepared with the Ion PGM™ Template IA 500 kit. This was followed by enriching the template-positive Ion Sphere particles. Samples were loaded on to Ion 316™ Chip Kit v2 and sequencing was carried out using the Ion PGM™ Hi-Q™ sequencing kit. The data was analyzed using Torrent Suite 5.0.4 for read filtering, base calling, barcode filtering, and alignment of reads to the human genome hg19 reference sequence. For data analysis, the samples were processed through the Ion Reporter™ Software version 5.10 using the Re-seq low-pass whole-genome aneuploidy workflow that can detect aneuploidies greater than around 10 MB in size. The decimal-level copy number gain or loss calls were enabled in the mosaic detection workflow. The Re-seq Mosaic PGS w1.1 v 5.10 workflow was used for mosaicism detection. Visualization of the analysis can be viewed in Integrative Genome Viewer (IGV)

version 5.0, and the scoring of aneuploidies was based on visualization of the IGV profile indicating losses and gains of the whole chromosome coupled with confidence and precision metrics. Embryos were further evaluated and scored based on the Median Absolute Pairwise Difference (MAPD) value, the number of reads obtained, and the coverage value.

Results

The study consisted of a total of 357 couples who had opted for PGT in the years 2016-2019 and chromosomal abnormality was detected in 22 patients in either of partners. The frequency of the chromosomal abnormality was observed to be 2.3% (11/468) in both male and female partners. The various chromosomal abnormalities observed are summarised in table 1. The median age of females was 31.6 (range 22-43 years) and males was 34 (range 27-39). A total of 341 oocytes were retrieved; the maturation rate of oocytes was

Table 1. Karyotype findings of the couples undergoing PGT-SR

| Karyotype | Number of subjects | Type | Origin | History | |
|----------------------------|--------------------|-------------------------------------|----------|---------------------------|--|
| 46,XX,t(10;14)(p13;q24) | 1 | | | Primary infertility | |
| 46,XX,t(8;12)(p11.2;q24.3) | 1 | | | 3 miscarriages | |
| 46,XX,t(6;7)(q25;q22) | 1 | | | 2 failed IVF cycles | |
| 46,XX,t(1;6)(p36.1;q13) | 1 | | Maternal | Primary infertility | |
| 46,XX,t(11;22)(q23;q11.2) | 1 | | | Primary infertility | |
| 46,XX,t(5;9)(q22;p22) | 1 | | | 3 miscarriages | |
| 46,XX,t(5;8)(q31;p22) | 1 | | | 2 failed IVF cycles | |
| 46,XX,t(7;13)(p13;q22) | 1 | | | 2 failed IVF cycles | |
| 46,XY,t(2;17)(q31;p13) | 1 | Reciprocal translocation (n=16) | | | Primary infertility |
| 46,XY,t(7;17)(p22;p11) | 1 | | | 2 miscarriages | |
| 46,XY,t(6;11)(p21;q23) | 1 | | | Primary infertility | |
| 46,XY,t(9;22)(q34;q11) | 1 | | | Primary infertility | |
| 46,XY,t(4;21)(q25;q22) | 1 | | | Paternal | 1 biochemical pregnancy 3 failed IVF cycles |
| 46,XY,t(4;18)(p12;q11.2) | 1 | | | | 3 miscarriages |
| 46,XY,t(8;15)(q13;q24) | 1 | | | 1 miscarriage | |
| 46,XY,t(14;21)(q22;q22.1) | 1 | | | Primary infertility | |
| 45,XX,der(13;14)(q10;q10) | 2 | Robertsonian translocation (n=3) | Maternal | Primary infertility | |
| 45,XY,der(13;14)(q10;q10) | 1 | | Paternal | 2 miscarriages | |
| 46,XX,inv(10)p11.2q21.2 | 1 | | Maternal | Primary infertility | |
| 46,XY,inv(5)(p15.1q31) | 1 | Inversion (n=3) | | 1 miscarriage | |
| 46X,inv(Y)(p11.2;q11.23) | 1 | | Paternal | 2 biochemical pregnancies | |
| 46X,inv(Y)(p11.2;q11.23) | 1 | | | 1 failed IVF cycle | |

Table 2. PGT-SR results and the pregnancy outcome in the study group

| PGT-SR | Frequency |
|---|---------------|
| Number of successfully biopsied embryos (mean±SD) | 87 (3.7±1.3) |
| Chromosomally normal embryos | 34.5% (30/87) |
| Aneuploid embryos (%) | 65.5% (57/87) |
| Monosomy (%) | 14% (8/57) |
| Trisomy (%) | 17.5% (10/57) |
| Two chromosome abnormalities (%) | 40.4% (23/57) |
| Multiple aneuploidies (%) | 19.3% (11/57) |
| Sex chromosome abnormality (%) | 3.5% (2/57) |
| Mosaicism (%) | 5.3% (3/57) |
| Pregnancy outcome | |
| Number of embryo transfer (ET) | 18 |
| Clinical pregnancy per ET (%) | 72.2% (13/18) |
| Live birth per ET (%) | 66.6% (12/18) |
| Miscarriage per clinical pregnancy | 7.7% (1/13) |

70.9% (242/341) and 194 oocytes were fertilized with a fertilization rate of 80.1% (Supplementary table 1).

Eighty-seven embryos were successfully biopsied and PGT-SR was performed on the same. A total of 30 (34.5%) were observed to be chromosomally balanced or normal and 57 (65.5%) were aneuploid. The frequency and the types of aneuploidies are listed in table 2. Of the 22 patients, 18 had at least one healthy embryo for transfer. In three patients, all the embryos tested were chromosomally abnormal as a result of unbalanced translocations, sporadic aneuploidies or combined abnormalities, and one patient had 2 euploid/balanced embryos for transfer, but both embryos did not survive thawing process and consequently, there was no transfer. The clinical pregnancy rate

per embryo transfer was observed to be 72.2% (13/18), live birth per embryo transfer was 66.6% (12/18), and miscarriage rate per pregnancy was 7.7% (1/13). Detailed profiles and ploidy status of the embryos based on PGT-SR and pregnancy rates are available in supplementary table 2.

Table 3 provides details of the unbalanced, sporadic aneuploidy and euploidy rates in the patients with three types of balanced chromosomal rearrangements which were observed in this study: reciprocal translocations (n=16), Robertsonian translocations (n=3), and inversions (n=3).

In subjects with reciprocal translocations, a total of 65 embryos were tested, of which 45 embryos were aneuploid, consisting of 30 (46.1%) embryos with inherited (unbalanced) translocation and 11 embryos (16.9%) with sporadic aneuploidies.

Table 3. Unbalanced translocation, sporadic aneuploidy, and euploidy rates

| | Number of embryos | Unbalanced translocation rate, % | Sporadic aneuploidy rate, % | Total abnormality rate, % * | Euploidy rate, % |
|-----------------------------------|-------------------|----------------------------------|-----------------------------|-----------------------------|------------------|
| Total | 87 | 39.1% | 21.8% | 65.5% | 34.5% |
| Maternal | 53 | 41.5% | 24.5% | 67.9% | 32.1% |
| Paternal | 34 | 38.3% | 23.5% | 61.8% | 38.2% |
| Reciprocal translocation | 65 | 46.1% | 16.9% | 69.2% | 30.8% |
| Robertsonian translocation | 13 | 23.1% | 46.1% | 69.2% | 30.8% |
| Inversion | 9 | 11.1% | 22.2% | 33.3% | 66.7% |

* Unbalanced translocation, sporadic aneuploidy and combined abnormality

Among 13 embryos from patients with Robertsonian translocations, 9 abnormal embryos were identified, consisting of 3 embryos (23.1%) with inherited (unbalanced) translocations and 6 embryos (46.1%) with sporadic aneuploidies. In the inversion carrier group, 9 embryos were tested, of which 3 embryos were aneuploid (33.3%), consisting of 1 (11.1%) embryo with inherited (unbalanced) translocation and 2 embryos (22.2%) with sporadic aneuploidies. The percentages of normal and abnormal embryos were calculated based on whether the balanced chromosomal translocation was present maternally or paternally (Table 3).

Discussion

In a couple, even if one of the partners has a translocation or an inversion, they may have longstanding infertility or recurrent implantation failure (16, 17). Balanced translocation or inversion carriers increase the rate of aneuploid gametes as a result of unequal exchanges and improper pairing of chromosomes during meiosis (18, 19). Alfarawati et al. showed that the group of embryos with Robertsonian translocation carriers exhibited mitotic interchromosomal effect due to mal-segregation which could be the probable cause of sporadic aneuploidies (20).

Studies have shown embryonic aneuploidy as one of the major reasons for failure of implantation and miscarriage. In cases where either the male or female partner is a carrier of a balanced translocation, about two thirds of the produced gametes will be genetically imbalanced and only one third will be balanced (either normal or balanced translocation) according to chromatid segregation during the first meiotic division (21). Thus, two thirds of the generated embryos following fertilization will be genetically abnormal which may either fail to implant or be aborted. Sugiura-Ogasawara et al. showed that frequencies of implantation failures and/or miscarriages in patients with reciprocal translocations (68.08%), Robertsonian translocations (36.4%) or inversions (42.9%) were much higher than in the normal population (28.3%) because of these scenarios (22).

The PGT-SR method has proven to be very effective and sensitive for the identification of whole chromosome and partial aneuploidies which can lead to miscarriages, implantation failures or live born infants with congenital anomalies. The method has been validated for unbalanced trans-

locations using NGS based Ion Torrent™ platform and the recorded smallest detectable segmental aneuploidy was 5 *Mbp* in size (23). In our PGT-SR cycles, 39.1% of embryos contained unbalanced translocations and 21.8% contained sporadic aneuploidies. This resulted in an aneuploidy rate of 65.5% which is similar to the percentage observed in other PGT-SR studies (24-27). The percentage of aneuploid embryos in IVF patients without balanced chromosomal rearrangements was observed to be 22.7-35.5% (28).

The PGT-SR outcome of embryos of translocation and inversion carrier groups was compared to determine the rates of unbalanced and sporadic aneuploidy. The group with reciprocal translocation carrier had a higher percentage of embryos with unbalanced translocations (46.1%) compared to embryos with sporadic aneuploidies (16.9%). On the contrary, embryos with sporadic aneuploidies were observed to be higher in the Robertsonian translocation carrier group. Fodina et al. showed in their study that the reciprocal translocation carrier group had embryos with unbalanced translocations at a rate that was 4 times higher than embryos with sporadic aneuploidies, while the Robertsonian translocation group had 5 times more embryos with sporadic aneuploidies in comparison to embryos with unbalanced translocations (22, 29, 30). Our study showed similar patterns, with the translocation carrier group exhibiting three times higher unbalanced translocations compared to sporadic aneuploidies.

No differences in percentages of normal versus abnormal embryos were observed irrespective of maternal or paternal carrier of the balanced chromosomal translocation as shown in table 3. A study by Idowu et al. also showed a similar trend where embryonic aneuploidies were observed to be similar in both maternal and paternal carriers of balanced chromosomal rearrangements (27).

Generally, twenty-four embryos in eighteen couples were transferred in this study. Five patients had no clinical pregnancy and one patient had a miscarriage at 15.4 weeks. The rate of live births was 66.6% per embryo transfer which is similar to the study conducted by Idowu et al., demonstrating similar live birth rate (31). Moreover, it is important to note that miscarriages or implantation failures are also associated with factors such as abnormal uterine anatomy, abnormal immunological response, and the non-receptive endometrium and that these factors could also affect the chances of a successful pregnancy in spite of ensuring that

only one euploid embryo was transferred (21). In such cases, these other factors also may need to be assessed and addressed.

Conclusion

The results of our study lead us to conclude that the number of euploid embryos in couples with a balanced translocation carrier is much lower than the normal population and that PGT-SR could increase the rate of clinical pregnancies and live births in such couples by enabling the transfer of chromosomally balanced or euploid embryos. This not only provides the couple with a high chance of having a normal child but can also reduce the chances of implantation failures and miscarriages which can be extremely traumatic.

Conflict of Interest

The authors declare no conflict of interest.

References

- Zorrilla M, Yatsenko AN. The genetics of infertility: current status of the field. *Curr Genet Med Rep*. 2013;1(4):1-22.
- Pylyp LY, Spinenko LO, Verhoglyad NV, Kashevarova OO, Zukin VD. [Chromosomal abnormalities in patients with infertility]. *Tsitol Genet*. 2015; 49(3):33-9. Russian.
- Liu Y, Kong XD, Wu QH, Li G, Song L, Sun YP. Karyotype analysis in large-sample infertile couples living in Central China: a study of 14965 couples. *J Assist Reprod Genet*. 2013;30(4):547-53.
- Kayed HF, Mansour RT, Aboulghar MA, Serour GI, Amer AE, Abdrazik A. Screening for chromosomal abnormalities in 2650 infertile couples undergoing ICSI. *Reprod Biomed Online*. 2006;12(3):359-70.
- Madan K, Nieuwint AW, van Bever Y. Recombination in a balanced complex translocation of a mother leading to a balanced reciprocal translocation in the child. Review of 60 cases of balanced complex translocations. *Hum Genet*. 1997;99(6): 806-15.
- Foresta C, Ferlin A, Gianaroli L, Dallapiccola B. Guidelines for the appropriate use of genetic tests in infertile couples. *Eur J Hum Genet*. 2002;10(5):303-12.
- Zhang YP, Xu JZ, Yin M, Chen MF, Ren DL. [Pregnancy outcomes of 194 couples with balanced translocations]. *Zhonghua Fu Chan Ke Za Zhi*. 2006;41(9):592-6. Chinese.
- Priya PK, Mishra VV, Roy P, Patel H. A study on balanced chromosomal translocations in couples with recurrent pregnancy loss. *J Hum Reprod Sci*. 2018;11(4):337-42.
- ESHRE PGT-SR/PGT-A Working Group, Coonen E, Rubio C, Christopikou D, Dimitriadou E, Gontar J, et al. ESHRE PGT Consortium good practice recommendations for the detection of structural and numerical chromosomal aberrations. *Hum Reprod Open*. 2020;2020(3):hoaa017.
- Martín J, Cervero A, Mir P, Martínez-Conejero JA, Pellicer A, Simón C. The impact of next-generation sequencing technology on preimplantation genetic diagnosis and screening. *Fertil Steril*. 2013; 99(4):1054-61.
- Yang Z, Lin J, Zhang J, Fong WI, Li P, Zhao R, et al. Randomized comparison of next-generation sequencing and array comparative genomic hybridization for preimplantation genetic screening: a pilot study. *BMC Med Genom*. 2015;8:30.
- Rooney DE, Czepulkowski. *Human Cytogenetics. a practical approach*. 1st ed. Oxford: IRL Press; 1992. 260 p.
- Shaffer LG, McGowan J, Schmid M. *ISCN 2013 An international system for human cytogenetic nomenclature*. Published in collaboration with cytogenetic and genome research. Switzerland: Karger; 2013. 141 p.
- Merrion K, Maisenbacher M. Pericentric inversion (Inv) 9 variant-reproductive risk factor or benign finding? *J Assist Reprod Genet*. 2019;36(12):2557-61.
- Jungheim ES, Meyer MF, Broughton DE. Best practices for controlled ovarian stimulation in in vitro fertilization. *Semin Reprod Med*. 2015;33(2): 77-82.
- Stephenson MD, Sierra S. Reproductive outcomes in recurrent pregnancy loss associated with a parental carrier of a structural chromosome rearrangement. *Hum Reprod*. 2006;21(4):1076-82.
- Munné S. Analysis of chromosome segregation during preimplantation genetic diagnosis in both male and female translocation heterozygotes. *Cytogenet Genome Res*. 2005;111(3-4):305-9.
- Vozdova M, Kasikova K, Oracova E, Prinosilova P, Rybar R, Horinova V, et al. The effect of the swim-up and hyaluronan-binding methods on the frequency of abnormal spermatozoa detected by FISH and SCSA in carriers of balanced chromosomal translocations. *Hum Reprod*. 2012;27(3): 930-7.
- Ishikawa T, Shiotani M, Izumi Y, Hashimoto H, Kokeguchi S, Goto S, et al. Fertilization and pregnancy using cryopreserved testicular sperm for in-

- tracytoplasmic sperm injection with azoospermia. *Fertil Steril.* 2009;92(1):174-9.
20. Lledo B, Ortiz JA, Morales R, Ten J, de la Fuente PE, Garcia-Ochoa C, et al. The paternal effect of chromosome translocation carriers observed from meiotic segregation in embryos. *Hum Reprod.* 2010;25(7):1843-8.
 21. Morin SJ, Eccles J, Iturriaga A, Zimmerman RS. Translocations, inversions and other chromosome rearrangements. *Fertil Steril.* 2017;107(1):19-26.
 22. Alfarawati S, Fragouli E, Colls P, Wells D. Embryos of robertsonian rranslocation carriers exhibit a mitotic interchromosomal effect that enhances genetic instability during early development. *PLoS Genet.* 2012;8(10):e1003025.
 23. Simon A, Laufer N. Assessment and treatment of repeated implantation failure (RIF). *J Assist Reprod Genet.* 2012;29(11):1227-39.
 24. Sugiura-Ogasawara M, Ozaki Y, Sato T, Suzumori N, Suzumori K. Poor prognosis of recurrent aborters with either maternal or paternal reciprocal translocations. *Fertil Steril.* 2004;81(2):367-73.
 25. Bono S, Biricik A, Spizzichino L, Nuccitelli A, Minasi MG, Greco E, et al. Validation of a semiconductor next-generation sequencing based protocol for preimplantation genetic diagnosis of Reciprocal translocations. *Prenat Diagn.* 2015;35(10):938-44.
 26. Zhang W, Liu Y, Wang L, Wang H, Ma M, Xu M, et al. Clinical application of next-generation sequencing in preimplantation genetic diagnosis cycles for Robertsonian and reciprocal translocations. *J Assist Reprod Genet.* 2016;33(7):899-906.
 27. Idowu D, Merrion K, Wemmer N, Mash JG, Petersen B, Kijacic D, et al. Pregnancy outcomes following 24-chromosome preimplantation genetic diagnosis in couples with balanced Reciprocal or Robertsonian translocations. *Fertil Steril.* 2015;103(4):1037-42.
 28. Treff NR, Northrop LE, Kasabwala K, Su J, Levy B, Scott RT Jr. Single nucleotide polymorphism microarray-based concurrent screening of 24-chromosome aneuploidy and unbalanced translocations in preimplantation human embryos. *Fertil Steril.* 2011;95(5):1606-12.e1-2.
 29. Alfarawati S, Fragouli E, Colls P, Wells D. First births after preimplantation genetic diagnosis of structural chromosome abnormalities using comparative genomic hybridization and microarray analysis. *Hum Reprod.* 2011;26(6):1560-74.
 30. Franasiak JM, Forman EJ, Hong KH, Werner MD, Upham KM, Treff NR, et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophoctoderm biopsies evaluated with comprehensive chromosomal screening. *Fertil Steril.* 2014;101(3):656-663.e1.
 31. Fodina V, Dudorova A, Alksere B, Dzalbs A, Vedmedovska N, Anderson S, et al. The application of PGT-A for carriers of balanced structural chromosomal rearrangements. *Gynecol Endocrinol.* 2019;35(sup 1):18-23.
 32. Rius M, Obradors A, Daina G, Ramos L, Pujol A, Martínez-Passarell O, et al. Detection of unbalanced chromosome segregations in preimplantation genetic diagnosis of translocations by short comparative genomic hibridization. *Fertil Steril.* 2011;96(1):134-42.
 33. Huang C, Jiang W, Zhu Y, Li H, Lu J, Yan J, et al. Pregnancy outcomes of reciprocal translocation carriers with two or more unfavorable pregnancy histories: before and after preimplantation genetic testing. *J Assist Reprod Genet.* 2019;36(11):2325-31.

Supplementary

Supplementary Table 1. General features of the studied population

| | Female carriers | Male carriers | Total |
|--|------------------------|----------------------|-----------------|
| Number of couples | 11 | 11 | 22 |
| Mean age of the carrier | 31.6 (22-43) | 34 (27-39) | |
| Type of infertility | | | |
| Primary (%) | | | 9 (41%) |
| Secondary (%) | | | 13 (59%) |
| Type of chromosomal abnormality | | | |
| Reciprocal translocation | 8 | 8 | 16 |
| Robertsonian translocation | 2 | 1 | 3 |
| Inversion | 1 | 2 | 3 |
| Number of oocytes retrieved (mean±SD) | | | 341 (15.5±7.75) |
| Maturation rate of oocytes (%) | | | 70.9% (242/341) |
| Fertilization rate (%) | | | 80.1% (194/242) |
| Cleavage rate (%) | | | 98.4% (191/194) |

Supplementary Table 2. Detailed profile and the ploidy status of the embryos based on PGT-SR and their pregnancy outcome

| Karyotype | | | | | | PGT-SR embryo status | Number of embryos transferred | Clinical pregnancy/ outcome |
|----------------------------|-----------|-----|------------|---------|----------|---|-------------------------------|-----------------------------|
| | Retrieved | MII | Fertilized | Cleaved | Biopsied | | | |
| 46,XX,t(10;14)(p13;q24) | 8 | 8 | 7 | 7 | 3 | 2 x normal Unbalanced (-14, -22) | 1 | Positive/Aborted |
| 46,XX,t(8;12)(p11.2;q24.3) | 13 | 6 | 6 | 6 | 5 | 2 x normal Multiple aneuploidies Unbalanced (-8) Unbalanced (+8, -12) | 2 | Positive/Delivered |
| 46,XX,t(6;7)(q25;q22) | 23 | 12 | 10 | 10 | 5 | 2 x normal Unbalanced (-6, +7, -16) Unbalanced (-6, +7) Unbalanced (-7) | 1 | Negative |
| 46,XY,t(7;17)(p22;p11) | 6 | 6 | 6 | 6 | 4 | Normal 2 X multiple aneuploidies Unbalanced (-17) | 1 | Negative |
| 46,XX, t(1;6)(p36.1;q13) | 15 | 13 | 5 | 5 | 4 | Unbalanced (-6) Mosaic trisomy 6 Multiple aneuploidies Unbalanced (+1, -6) | 0 | NA |
| 46,XY,t(2;17)(q31;p13) | 12 | 11 | 6 | 6 | 3 | Unbalanced (-2) Unbalanced (+2) | 1 | Positive/Delivered |
| 46,XY,t(6;11)(p21;q23) | 7 | 6 | 4 | 4 | 2 | Normal Unbalanced (-6, +11) | 1 | Positive/Delivered |
| 46,XX,t(11;22)(q23;q11.2) | 27 | 22 | 19 | 19 | 6 | Normal Sex chromosome aneuploidy Unbalanced (+11, -22) 2 X unbalanced (-11, +22) Unbalanced (+11) | 1 | Negative |

Contd. Supplementary Table 2. Detailed profile and the ploidy status of the embryos based on PGT-SR and their pregnancy outcome

| Karyotype | | | | | | PGT-SR embryo status | Number of embryos transferred | Clinical pregnancy/ outcome |
|---------------------------|-----------|-----|------------|---------|----------|--|----------------------------------|--------------------------------|
| | Retrieved | MII | Fertilized | Cleaved | Biopsied | | | |
| 46,XY,t(9;22)(q34;q11) | 21 | 19 | 16 | 15 | 4 | 3 X normal Mosaic partial trisomy 6 (25%) 2 X normal | 2 | Positive/Delivered |
| 46,XX,t(5;9)(q22;p22) | 19 | 10 | 8 | 8 | 7 | 3 X unbalanced (+5, -9) 2 X unbalanced (-5, +9) | 2 | Positive/Delivered |
| 46,XX,t(5;8)(q31;p22) | 16 | 10 | 10 | 10 | 4 | 2 X normal Trisomy 7 Sex chromosome aneuploidy | 2 | Positive/Delivered |
| 46,XX,t(7;13)(p13;q22) | 20 | 19 | 15 | 15 | 6 | Normal 2 X unbalanced (+7, -13) Unbalanced (+7, -13, -11) Unbalanced (-7, +13) Multiple aneuploidies | 1 | Negative |
| 46,XY,t(4;21)(q25;q22) | 6 | 4 | 3 | 3 | 2 | Unbalanced (+4, -21) Unbalanced (-4, +21) | 0 | NA |
| 46,XY,t(4;18)(p12;q11.2) | 11 | 8 | 6 | 6 | 3 | Normal Multiple mosaic aneuploidies Unbalanced (-4, +8) | 1 | Positive/Delivered |
| 46,XY,t(8;15)(q13;q24) | 31 | 20 | 18 | 17 | 4 | Normal Trisomy 6 Trisomy 3 Unbalanced (+8, -15) Unbalanced (+3; +6) | 1 | Positive/Delivered |
| 46,XY,t(14;21)(q22;q22.1) | 8 | 4 | 3 | 3 | 3 | Unbalanced (+14; -21) Unbalanced (-14; +21) | 0 | NA |
| 45,XX,der(13;14)(q10;q10) | 27 | 2 | 1 | 1 | 3 | 2 X normal Multiple aneuploidies | 0 | NA |
| 45,XY,der(13;14)(q10;q10) | 12 | 12 | 9 | 9 | 3 | Normal Multiple aneuploidies Unbalanced (+14) | 1 | Negative |

Contd. Supplementary Table 2. Detailed profile and the ploidy status of the embryos based on PGT-SR and their pregnancy outcome

| Karyotype | | | | | | PGT-SR embryo status | Number of embryos transferred | Clinical pregnancy/ outcome |
|---------------------------|-----------|-----|------------|---------|----------|-------------------------|----------------------------------|--------------------------------|
| | Retrieved | MII | Fertilized | Cleaved | Biopsied | | | |
| 45,XX,der(13;14)(q10;q10) | 16 | 15 | 12 | 12 | 7 | Normal | 1 | Positive/Delivered |
| | | | | | | Unbalanced (-16) | | |
| | | | | | | Unbalanced (+11) | | |
| | | | | | | Unbalanced (+20) | | |
| | | | | | | Unbalanced (+13) | | |
| | | | | | | Unbalanced (-14) | | |
| Unbalanced (-19) | | | | | | | | |
| 46,XY,inv(5)(p15.1q31) | 5 | 4 | 4 | 4 | 3 | Normal | 1 | Positive/Delivered |
| | | | | | | Multiple aneuploidies | | |
| | | | | | | Unbalanced (+5) | | |
| 46,XX,inv(10)p11.2q21.2 | 11 | 6 | 5 | 4 | 3 | 2X normal | 2 | Positive/Delivered |
| | | | | | | Multiple aneuploidies | | |
| 46X,inv(Y)(p11.2;q11.23) | 17 | 16 | 14 | 14 | 3 | 3X normal | 2 | Positive/Delivered |